학술논문
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Document Type
Article
Author
Barouch, Dan H; Tomaka, Frank L; Wegmann, Frank; Stieh, Daniel J; Alter, Galit; Robb, Merlin L; Michael, Nelson L; Peter, Lauren; Nkolola, Joseph P; Borducchi, Erica N; Chandrashekar, Abishek; Jetton, David; Stephenson, Kathryn E; Li, Wenjun; Korber, Bette; Tomaras, Georgia D; Montefiori, David C; Gray, Glenda; Frahm, Nicole; McElrath, M Juliana; Baden, Lindsey; Johnson, Jennifer; Hutter, Julia; Swann, Edith; Karita, Etienne; Kibuuka, Hannah; Mpendo, Juliet; Garrett, Nigel; Mngadi, Kathy; Chinyenze, Kundai; Priddy, Frances; Lazarus, Erica; Laher, Fatima; Nitayapan, Sorachai; Pitisuttithum, Punnee; Bart, Stephan; Campbell, Thomas; Feldman, Robert; Lucksinger, Gregg; Borremans, Caroline; Callewaert, Katleen; Roten, Raphaele; Sadoff, Jerald; Scheppler, Lorenz; Weijtens, Mo; Feddes-de Boer, Karin; van Manen, Daniëlle; Vreugdenhil, Jessica; Zahn, Roland; Lavreys, Ludo; Nijs, Steven; Tolboom, Jeroen; Hendriks, Jenny; Euler, Zelda; Pau, Maria G; Schuitemaker, Hanneke
Source
The Lancet; July 2018, Vol. 392 Issue: 10143 p232-243, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and preclinical studies. We aimed to evaluate mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel studies in humans and rhesus monkeys to define the optimal vaccine regimen to advance into clinical efficacy trials.